Clinical Trial Update: Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pirfenidone for focal segmental glomerulosclerosis (kidney fibrosis) has completed and posted results in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Focal Segmental Glomerulosclerosis
• Nephrotic Syndrome

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Fibrosis, Focal Glomerulosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2012-06-01